156 related articles for article (PubMed ID: 37942576)
21. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
Niu L; Gao Z; Cui Y; Yang X; Li H
Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418
[TBL] [Abstract][Full Text] [Related]
22. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
[TBL] [Abstract][Full Text] [Related]
23. Mode of interaction of TRIP13 AAA-ATPase with the Mad2-binding protein p31comet and with mitotic checkpoint complexes.
Miniowitz-Shemtov S; Eytan E; Kaisari S; Sitry-Shevah D; Hershko A
Proc Natl Acad Sci U S A; 2015 Sep; 112(37):11536-40. PubMed ID: 26324890
[TBL] [Abstract][Full Text] [Related]
24. Thyroid hormone receptor interacting protein 13 (TRIP13) AAA-ATPase is a novel mitotic checkpoint-silencing protein.
Wang K; Sturt-Gillespie B; Hittle JC; Macdonald D; Chan GK; Yen TJ; Liu ST
J Biol Chem; 2014 Aug; 289(34):23928-37. PubMed ID: 25012665
[TBL] [Abstract][Full Text] [Related]
25. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.
Li C; Xia J; Franqui-Machin R; Chen F; He Y; Ashby TC; Teng F; Xu H; Liu D; Gai D; Johnson SK; van Rhee F; Janz S; Shaughnessy JD; Tricot G; Frech I; Zhan F
J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061780
[TBL] [Abstract][Full Text] [Related]
26. p31
Sarangi P; Clairmont CS; Galli LD; Moreau LA; D'Andrea AD
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26795-26803. PubMed ID: 33051298
[TBL] [Abstract][Full Text] [Related]
27. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
Xiao Z; Li M; Zhang X; Rong X; Xu H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
[TBL] [Abstract][Full Text] [Related]
28. Mouse HORMAD1 and HORMAD2, two conserved meiotic chromosomal proteins, are depleted from synapsed chromosome axes with the help of TRIP13 AAA-ATPase.
Wojtasz L; Daniel K; Roig I; Bolcun-Filas E; Xu H; Boonsanay V; Eckmann CR; Cooke HJ; Jasin M; Keeney S; McKay MJ; Toth A
PLoS Genet; 2009 Oct; 5(10):e1000702. PubMed ID: 19851446
[TBL] [Abstract][Full Text] [Related]
29. Laser-induced radiation microbeam technology and simultaneous real-time fluorescence imaging in live cells.
Botchway SW; Reynolds P; Parker AW; O'Neill P
Methods Enzymol; 2012; 504():3-28. PubMed ID: 22264527
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab.
Banerjee R; Liu M; Bellile E; Schmitd LB; Goto M; Hutchinson MND; Singh P; Zhang S; Damodaran DPV; Nyati MK; Spector ME; Ward B; Wolf G; Casper K; Mierzwa M; D'Silva NJ
Mol Ther; 2022 Jan; 30(1):468-484. PubMed ID: 34111559
[TBL] [Abstract][Full Text] [Related]
31. Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway.
Xiao W; Xu Z; Chang S; Li B; Yu D; Wu H; Xie Y; Wang Y; Xie B; Sun X; Kong Y; Lan X; Bu W; Chen G; Gao L; Wu X; Shi J; Zhu W
Cancer Lett; 2019 Mar; 444():45-59. PubMed ID: 30583070
[TBL] [Abstract][Full Text] [Related]
32. The AAA+ ATPase TRIP13 remodels HORMA domains through N-terminal engagement and unfolding.
Ye Q; Kim DH; Dereli I; Rosenberg SC; Hagemann G; Herzog F; Tóth A; Cleveland DW; Corbett KD
EMBO J; 2017 Aug; 36(16):2419-2434. PubMed ID: 28659378
[TBL] [Abstract][Full Text] [Related]
33. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
[TBL] [Abstract][Full Text] [Related]
34. Mouse pachytene checkpoint 2 (trip13) is required for completing meiotic recombination but not synapsis.
Li XC; Schimenti JC
PLoS Genet; 2007 Aug; 3(8):e130. PubMed ID: 17696610
[TBL] [Abstract][Full Text] [Related]
35. TRIP13 Induces Nedaplatin Resistance in Esophageal Squamous Cell Carcinoma by Enhancing Repair of DNA Damage and Inhibiting Apoptosis.
Zhang LT; Ke LX; Wu XY; Tian HT; Deng HZ; Xu LY; Li EM; Long L
Biomed Res Int; 2022; 2022():7295458. PubMed ID: 35601150
[TBL] [Abstract][Full Text] [Related]
36. The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma.
Gkotzamanidou M; Terpos E; Dimopoulos MA; Souliotis VL
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555311
[TBL] [Abstract][Full Text] [Related]
37. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.
Zhou XY; Shu XM
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159
[TBL] [Abstract][Full Text] [Related]
38. TRIP13 exerts a cancer-promoting role in cervical cancer by enhancing Wnt/β-catenin signaling via ACTN4.
Liu X; Shen X; Zhang J
Environ Toxicol; 2021 Sep; 36(9):1829-1840. PubMed ID: 34061428
[TBL] [Abstract][Full Text] [Related]
39. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
López-Iglesias AA; Herrero AB; Chesi M; San-Segundo L; González-Méndez L; Hernández-García S; Misiewicz-Krzeminska I; Quwaider D; Martín-Sánchez M; Primo D; Paíno T; Bergsagel PL; Mehrling T; González-Díaz M; San-Miguel JF; Mateos MV; Gutiérrez NC; Garayoa M; Ocio EM
J Hematol Oncol; 2017 Jun; 10(1):127. PubMed ID: 28633670
[TBL] [Abstract][Full Text] [Related]
40. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
